24 September 2019

Up to 24% of patients with acute coronary syndromes present with ST-segment elevation myocardial infarction (STEMI) but show complete resolution of ST-segment elevation and symptoms before revascularization. Current guidelines do not clearly state whether these patients with transient STEMI should be treated with a STEMI-like or non–ST-segment elevation acute coronary syndrome–like intervention strategy.

Niels van Royen, theme Vascular damage, and colleagues, found out that patients with transient STEMI have limited infarction and well-preserved myocardial function in general, and delayed or immediate revascularization has no effect on functional outcome and clinical events up to 1 year. They have published their findings in JACC: Cardiovascular Interventions. 

Methods
In this multicenter trial, 142 patients with transient STEMI were randomized 1:1 to either delayed or immediate coronary intervention. Cardiac magnetic resonance imaging was performed at 4 days and at 4-month follow-up to assess infarct size and myocardial function. Clinical follow-up was performed at 4 and 12 months.

Results
In the delayed (22.7 h) and the immediate (0.4 h) invasive groups, final infarct size as a percentage of the left ventricle was very small (0.4% [interquartile range: 0.0% to 2.5%] vs. 0.4% [interquartile range: 0.0% to 3.5%]; p = 0.79), and left ventricular function was good (mean ejection fraction 59.3 ± 6.5% vs. 59.9 ± 5.4%; p = 0.63). In addition, the overall occurrence of major adverse cardiac events, consisting of death, recurrent infarction, and target lesion revascularization, up to 1 year was low and not different between both groups (5.7% vs. 4.4%, respectively; p = 1.00).


  • Want to know more about these subjects? Click on the buttons below for more news.

    Cardiology

Related news items


Grants for heart and kidney research Two awards to Radboudumc in Open Competition ENW-XS

21 July 2022

Two researchers from the Radboudumc receive a grant from the NWO within the Open Competition of the Exact and Natural Sciences. They are Thijs Eijsvogels, who studies the heart, and Pieter Leermakers, who studies the kidneys. 

read more

Veni grants for RIMLS researchers

16 December 2021 NWO has awarded 89 promising young scientists Veni funding of up to 280,000 euros. Three of them are from Radboud Institute of Molecular Life Sciences (RIMLS). They can develop their own research ideas over a period of three years. read more

Vote for the RIMLS Supervisor of the year

7 December 2021

This is your chance to vote for your favourite candidate for supervisor of the year! Support and promote your ideal supervisor from the three nominees: Siroon Bekkering, Gerald Verhaegh and Jo Zhou. Please submit your vote the 20th of December 2021 at the latest.

read more

Technology saves lives! 1.9 million euros from the Heart Foundation for developing smart watches

17 November 2021 Niels van Royen is proud to be part of this consortium, initiated by Judith Bonnes, to develop a wrist band for early detection of cardiac arrest. Together with Erasmus, Reinier de Graaf and Corsano Health. read more

The impact of Transradial Intervention (TRI) on digital hand perfusion

29 April 2019 Niels van Royen, theme Vascular damage, and colleagues, investigated the effect of TRI on digital perfusion by laser doppler perfusion imaging. They concluded in Circulation: Cardiovascular Interventions, that TRI is safe.  read more

Coronary angiography after cardiac arrest without ST-segment elevation

2 April 2019 Niels van Royen, theme Vascular damage, found out and published in NEJM, that among patients who had been successfully resuscitated after out-of-hospital cardiac arrest and had no signs of STEMI, a strategy of immediate angiography was not found to be better than a strategy of delayed angiography. read more